JP2019536816A - 高血圧の処置のための組成物 - Google Patents

高血圧の処置のための組成物 Download PDF

Info

Publication number
JP2019536816A
JP2019536816A JP2019547198A JP2019547198A JP2019536816A JP 2019536816 A JP2019536816 A JP 2019536816A JP 2019547198 A JP2019547198 A JP 2019547198A JP 2019547198 A JP2019547198 A JP 2019547198A JP 2019536816 A JP2019536816 A JP 2019536816A
Authority
JP
Japan
Prior art keywords
dose
pharmaceutical composition
diuretic
composition according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019547198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536816A5 (https=
Inventor
ロジャース，アンソニー
チャウ，クララ
Original Assignee
ザ ジョージ インスティテュート フォー グローバル ヘルス
ザ ジョージ インスティテュート フォー グローバル ヘルス
ザ ユニバーシティー オブ シドニー
ザ ユニバーシティー オブ シドニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジョージ インスティテュート フォー グローバル ヘルス, ザ ジョージ インスティテュート フォー グローバル ヘルス, ザ ユニバーシティー オブ シドニー, ザ ユニバーシティー オブ シドニー filed Critical ザ ジョージ インスティテュート フォー グローバル ヘルス
Publication of JP2019536816A publication Critical patent/JP2019536816A/ja
Publication of JP2019536816A5 publication Critical patent/JP2019536816A5/ja
Priority to JP2023017160A priority Critical patent/JP2023095844A/ja
Priority to JP2025036716A priority patent/JP2025102796A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019547198A 2016-11-15 2017-11-14 高血圧の処置のための組成物 Pending JP2019536816A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023017160A JP2023095844A (ja) 2016-11-15 2023-02-07 高血圧の処置のための組成物
JP2025036716A JP2025102796A (ja) 2016-11-15 2025-03-07 高血圧の処置のための組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/352,425 2016-11-15
US15/352,425 US10369156B2 (en) 2016-11-15 2016-11-15 Compositions for the treatment of hypertension
PCT/IB2017/001524 WO2018091967A1 (en) 2016-11-15 2017-11-14 Compositions for the treatment of hypertension

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023017160A Division JP2023095844A (ja) 2016-11-15 2023-02-07 高血圧の処置のための組成物

Publications (2)

Publication Number Publication Date
JP2019536816A true JP2019536816A (ja) 2019-12-19
JP2019536816A5 JP2019536816A5 (https=) 2020-12-24

Family

ID=62107049

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019547198A Pending JP2019536816A (ja) 2016-11-15 2017-11-14 高血圧の処置のための組成物
JP2023017160A Pending JP2023095844A (ja) 2016-11-15 2023-02-07 高血圧の処置のための組成物
JP2025036716A Pending JP2025102796A (ja) 2016-11-15 2025-03-07 高血圧の処置のための組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023017160A Pending JP2023095844A (ja) 2016-11-15 2023-02-07 高血圧の処置のための組成物
JP2025036716A Pending JP2025102796A (ja) 2016-11-15 2025-03-07 高血圧の処置のための組成物

Country Status (8)

Country Link
US (2) US10369156B2 (https=)
EP (2) EP4574136A3 (https=)
JP (3) JP2019536816A (https=)
CN (2) CN116603066A (https=)
AU (3) AU2017359607A1 (https=)
CA (1) CA3043835A1 (https=)
TW (1) TWI799397B (https=)
WO (1) WO2018091967A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10369156B2 (en) 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
KR20240096848A (ko) 2017-01-25 2024-06-26 더 조지 인스티튜트 포 글로벌 헬스 고혈압의 치료를 위한 조성물
US12521380B2 (en) 2017-01-25 2026-01-13 The George Institute for Global Health Compositions for the treatment of hypertension
EP3807898A1 (en) * 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
CA3103616A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
MX2021001043A (es) * 2018-07-26 2021-04-12 The George Inst For Global Health Composiciones para el tratamiento de hipertension.
JP2021536443A (ja) * 2018-08-25 2021-12-27 シーアールディー ファーマシューティカルズ インコーポレイティド 高血圧治療をサーカディアンリズムと同期させる
KR102900997B1 (ko) * 2019-12-11 2025-12-22 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
EP4649946A1 (en) * 2024-05-16 2025-11-19 Alba Research S.r.l. Compositions for treating arterial hypertension

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004514703A (ja) * 2000-12-01 2004-05-20 ノバルティス　アクチエンゲゼルシャフト 有機化合物の組合せ剤
JP2009256209A (ja) * 2006-02-17 2009-11-05 Gilead Colorado Inc 降圧療法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
ATE326240T2 (de) 2000-04-10 2006-06-15 Nicholas John Wald Zusammensetzung zur prävention kardiovaskulärer erkrankungen
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US20040198789A1 (en) 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
US20050187262A1 (en) 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
WO2005099700A1 (en) * 2004-04-06 2005-10-27 Merck & Co., Inc. Methods for the treatment of hypertension
US20070196510A1 (en) 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
US20070293552A1 (en) 2006-06-15 2007-12-20 Gorczynski Richard J Antihypertensive therapy method
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
CN101450211A (zh) 2007-12-07 2009-06-10 上海艾力斯医药科技有限公司 复方降压制剂
EP2575808A1 (en) 2010-05-28 2013-04-10 Mahmut Bilgic Combination of antihypertensive agents
CN101966190A (zh) 2010-07-17 2011-02-09 邬林祥 一种治疗高血压含氨氯地平和依普罗沙坦的复方制剂
CN102225203A (zh) 2011-06-29 2011-10-26 北京阜康仁生物制药科技有限公司 一种用于降低血压的药用组合物
US10918612B2 (en) 2013-01-22 2021-02-16 Markus Zwickl Combinations with 2-aminoethanesulfonic acid
CN106310278A (zh) 2016-08-01 2017-01-11 深圳奥萨制药有限公司 一种含叶酸的多联降压药物组合物
US10369156B2 (en) 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
KR20240096848A (ko) 2017-01-25 2024-06-26 더 조지 인스티튜트 포 글로벌 헬스 고혈압의 치료를 위한 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004514703A (ja) * 2000-12-01 2004-05-20 ノバルティス　アクチエンゲゼルシャフト 有機化合物の組合せ剤
JP2009256209A (ja) * 2006-02-17 2009-11-05 Gilead Colorado Inc 降圧療法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MID-LIFE HEALTH, vol. Vol.5, No.2, pp.78-83, JPN6021049022, 2014, ISSN: 0004892819 *
KIDNEY INTERNATIONAL, vol. Vol.75, pp.752-754, JPN6021049021, 2009, ISSN: 0004892820 *

Also Published As

Publication number Publication date
JP2025102796A (ja) 2025-07-08
EP4574136A2 (en) 2025-06-25
AU2025210908A1 (en) 2025-08-21
AU2023258387A1 (en) 2023-11-23
CN116603066A (zh) 2023-08-18
EP4574136A3 (en) 2025-09-17
CN110366414A (zh) 2019-10-22
EP3541379A4 (en) 2020-05-27
US20190314383A1 (en) 2019-10-17
TW201828988A (zh) 2018-08-16
AU2017359607A1 (en) 2019-06-06
EP3541379A1 (en) 2019-09-25
TWI799397B (zh) 2023-04-21
US10369156B2 (en) 2019-08-06
CA3043835A1 (en) 2018-05-24
US20180133227A1 (en) 2018-05-17
BR112019009859A2 (pt) 2019-08-20
AU2023258387B2 (en) 2025-05-29
JP2023095844A (ja) 2023-07-06
WO2018091967A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
JP2019536816A (ja) 高血圧の処置のための組成物
US12285415B2 (en) Compositions for the treatment of hypertension
JP7474738B2 (ja) 高血圧症の処置のための組成物
RU2828226C2 (ru) Композиции для лечения гипертензии
HK40116862A (zh) 用於治疗高血压的组合物
HK40092202A (zh) 用於治疗高血压的组合物
HK40129803A (en) Compositions for the treatment of hypertension
BR122024023236A2 (pt) Composição farmacêutica para o tratamento de hipertensão e uso da mesma
BR112019009859B1 (pt) Composição farmacêutica para o tratamento de hipertensão e uso da mesma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221011